ALB and hepatocellular carcinoma: Albumin-bilirubin (ALBI) grade has been proposed and validated to predict survival benefits for HCC patients receiving immunotherapy, we compared the area under the curve (AUC) and net reclassification improvements (NRI) in predictive performance between ATSI score and ALBI grade (Table S2).